帕博西尼和氟维司汀治疗HR+/ HER2-转移性乳腺癌患者的现实世界研究。

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-01-01 Epub Date: 2025-01-15 DOI:10.1080/14796694.2024.2442302

Nicholas Robert, Connie Chen, Justin Doan, Divea Venkatasetty, Janet L Espirito, Kathleen M Aguilar

{"title":"帕博西尼和氟维司汀治疗HR+/ HER2-转移性乳腺癌患者的现实世界研究。","authors":"Nicholas Robert, Connie Chen, Justin Doan, Divea Venkatasetty, Janet L Espirito, Kathleen M Aguilar","doi":"10.1080/14796694.2024.2442302","DOIUrl":null,"url":null,"abstract":"Aims: To investigate real-world treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who initiated first-line palbociclib-fulvestrant.Patients & methods: Retrospective observational study of iKnowMed electronic health records among patients who initiated first-line palbociclib-fulvestrant between 1 February 2016 and 31 December 2019 and were followed through 30 June 2020. Demographic, clinical, and treatment characteristics were evaluated descriptively. Endpoints including real-world progression-free survival, overall survival, time to chemotherapy, real-world duration of therapy, and time to next treatment were assessed using Kaplan-Meier methods from first-line treatment initiation.Results: 317 patients were included (median age 67.3 years, 90.5% post-menopausal, 36.9% bone-only disease, 15.9 months median follow-up). Among those with prior adjuvant treatment (n = 269), 66.2% (n = 178) had disease-free intervals less than 12 months. Median real-world progression-free survival was 19.6 months (95% CI 15.2-23.6).Conclusions: These results suggest favorable real-world clinical outcomes associated with first-line palbociclib-fulvestrant among patients with HR+/HER2- mBC. (clinical trial registration: NCT04498481).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"83-94"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759524/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant.\",\"authors\":\"Nicholas Robert, Connie Chen, Justin Doan, Divea Venkatasetty, Janet L Espirito, Kathleen M Aguilar\",\"doi\":\"10.1080/14796694.2024.2442302\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aims: To investigate real-world treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who initiated first-line palbociclib-fulvestrant.Patients & methods: Retrospective observational study of iKnowMed electronic health records among patients who initiated first-line palbociclib-fulvestrant between 1 February 2016 and 31 December 2019 and were followed through 30 June 2020. Demographic, clinical, and treatment characteristics were evaluated descriptively. Endpoints including real-world progression-free survival, overall survival, time to chemotherapy, real-world duration of therapy, and time to next treatment were assessed using Kaplan-Meier methods from first-line treatment initiation.Results: 317 patients were included (median age 67.3 years, 90.5% post-menopausal, 36.9% bone-only disease, 15.9 months median follow-up). Among those with prior adjuvant treatment (n = 269), 66.2% (n = 178) had disease-free intervals less than 12 months. Median real-world progression-free survival was 19.6 months (95% CI 15.2-23.6).Conclusions: These results suggest favorable real-world clinical outcomes associated with first-line palbociclib-fulvestrant among patients with HR+/HER2- mBC. (clinical trial registration: NCT04498481).\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"83-94\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759524/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2024.2442302\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2442302","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：研究激素受体阳性/人表皮生长因子2阴性（HR+/HER2-）转移性乳腺癌（mBC）患者使用一线帕博西利-氟维司汀治疗的现实世界治疗模式和结果。患者和方法：对2016年2月1日至2019年12月31日期间开始使用一线帕博西尼-氟维司汀的患者的iKnowMed电子健康记录进行回顾性观察研究，并随访至2020年6月30日。对人口学、临床和治疗特征进行描述性评价。终点包括实际无进展生存期、总生存期、化疗时间、实际治疗持续时间和下一次治疗时间，从一线治疗开始使用Kaplan-Meier方法进行评估。结果：纳入317例患者（中位年龄67.3岁，90.5%绝经后，36.9%仅骨疾病，中位随访15.9个月）。在先前接受辅助治疗的患者（n = 269）中，66.2% （n = 178）的无病间隔时间小于12个月。真实世界无进展生存期中位数为19.6个月（95% CI 15.2-23.6）。结论：这些结果表明一线palbociclib-fulvestrant在HR+/HER2- mBC患者中具有良好的实际临床结果。（临床试验注册号：NCT04498481）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant.

Aims: To investigate real-world treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who initiated first-line palbociclib-fulvestrant.

Patients & methods: Retrospective observational study of iKnowMed electronic health records among patients who initiated first-line palbociclib-fulvestrant between 1 February 2016 and 31 December 2019 and were followed through 30 June 2020. Demographic, clinical, and treatment characteristics were evaluated descriptively. Endpoints including real-world progression-free survival, overall survival, time to chemotherapy, real-world duration of therapy, and time to next treatment were assessed using Kaplan-Meier methods from first-line treatment initiation.

Results: 317 patients were included (median age 67.3 years, 90.5% post-menopausal, 36.9% bone-only disease, 15.9 months median follow-up). Among those with prior adjuvant treatment (n = 269), 66.2% (n = 178) had disease-free intervals less than 12 months. Median real-world progression-free survival was 19.6 months (95% CI 15.2-23.6).

Conclusions: These results suggest favorable real-world clinical outcomes associated with first-line palbociclib-fulvestrant among patients with HR+/HER2- mBC. (clinical trial registration: NCT04498481).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.